In this study, 43.9% had a mutant KRAS genotype, which means that, if KRAS mutational status testing is applied to select candidates for anti-EGFR MoAbs treatment, the proportion of Chinese CRC patients that would be excluded is similar to that of other countries. The gene discussed is EGFR; the disease is colorectal carcinoma.